Abstract
Background Glucocorticoids are used as anti-inflammatory and immunosuppressive drugs in the treatment of many inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus (SLE), but their use in treatment of severe inflammation in sepsis and shock is controversial. This is at least in part caused by the lack of information regarding responding cell types and the genes which are the targets of glucocorticoids in vivo. Here, we aim to get an overview of glucocorticoid regulated genes in blood cells and to describe their expression in health, mild and severe inflammation depending on cell type.
Methods and Findings We used 2 different sets of cortisol induced query genes in a gene expression correlation search of 375+ blood based gene transcription datasets to obtain 2 gene signatures of GC induction, either in the relative absence or in the presence of severe inflammation. Additional searches provided gene expression correlation profiles for separate immune cells and control tissues. Many well known GC target genes were recovered, as well as candidate GC regulated genes, which were further tested for upregulation by GC in vitro in different immune cells. Genes from GC signature 1, present in the relative absence of severe inflammation, and gene markers for cell type and inflammation were evaluated for expression correlation characteristics in a meta analysis of 62 datasets exluding severe inflammation, allowing delineation of a core group of GC induced genes including TSC22D3 and DDIT4. Several genes from this core group were highly upregulated in whole blood by circadian GC, and by GC treatment of healthy people, and suitable for combined use as biomarker of GC action, in the absence of severe inflammation. GC signature 2, present in severe inflammation, originated from gene expression in neutrophils and monocytes, as determined by correlation analysis using 38 datasets on severe inflammation, such as sepsis and trauma, and from gene expression profiles of isolated blood cells from sepsis patients. Genes expressed specifically in monocytes included VSIG4 and ADAMTS2, while genes such as OLAH and ARG1 were preferentially expressed in neutrophils, or expressed in both cell types such as CD163. GC driven signature 2 genes expressed in monocytes, included several markers for alternatively activated macrophages, that were strongly upregulated in severe inflammation. GC signature 2 was present in sepsis, trauma, and ARDS, and found in many other inflammatory diseases such as Kawasaki disease. The gene signature for cortisol induction in severe systemic inflammation might depend on elevated blood cortisol levels and/or the appearance of the distinct neutrophils and monocytes populations as seen in severe inflammation. This points to endogenous cortisol as an important factor for immunosuppression in vivo.
Conclusion We present a large number of cortisol regulated genes in different blood cells, obtained by transcriptomic meta-analysis, including gene markers that will be potentially useful for monitoring cortisol action in severe inflammation at the cellular level. We further demonstrate that gene induction by GCs in monocytes and neutrophils, associated with severe inflammation, is frequently present in many different inflammatory illnesses.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/ArthurJohannes/GCblood_repo
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data located at NCBI GEO database, and at the ArrayExpress repository
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
https://www.ncbi.nlm.nih.gov/gds